Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $725.00. The company’s sha...

BMO Capital Remains a Buy on Regeneron (REGN)

Insiders have been trading these 5 stocks: (($BX)), (($REGN)), (($SCHW)), (($TSE:CLS)) and (($GLW)). Here is a breakdown of their recent trades and...

Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a pivotal Phase ...

Regeneron’s New Study Targets Improved Outcomes in Multiple Myeloma

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron, with a price target of $750.00. The company’s ...

Evercore ISI Remains a Buy on Regeneron (REGN)

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals recently complet...

Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron today and set a price target of $870.00. The company’s shares opened today at $...

Regeneron (REGN) Gets a Buy from Jefferies

In a report released today, William Pickering from Bernstein maintained a Buy rating on Regeneron, with a price target of $781.00. The company’s sh...

Bernstein Sticks to Its Buy Rating for Regeneron (REGN)

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a critical study t...

Regeneron’s New Phase 3 Study on Mibavademab: A Potential Game-Changer for Generalized Lipodystrophy

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a new clinical stu...

Current Quarter	$8.29	Next Quarter	$6.75
Current Year	$34.84	Next Year	$32.42
QoQ Growth	-18.6%	YoY Growth	-6.9%
3Y EPS CAGR	-18.8%	Target Price	$755.22
Consensus	Buy	Upside	-0.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$755.90	+2.56%	1.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$755.90	+2.6%	1.43M
3
4
5
6

REGN

REGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel